The Efficacy of Chlorhexidine Gluconate Gel Dressing in Preventing Surgical Drain Site Infection
Primary Purpose
Drain Site Complication
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing
Sponsored by

About this trial
This is an interventional treatment trial for Drain Site Complication focused on measuring Tegaderm
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or older
- Receiving two surgical drains during one of the following types of operative procedures: breast reduction, breast augmentation, abdominoplasty, panniculectomy, brachioplasty, thigh lift, lower body lift, belt lipectomy, back latissimus dorsi reconstruction, bilateral breast reconstruction, or bilateral chest reconstruction. These drains may be in fairly close proximity to one another but they must emerge from different areas of the skin, that way they can be considered to be located in two different sites.
Exclusion Criteria:
- Concurrent implantation of any foreign objects, such as a breast implant
- Patients who receive postoperative antibiotics without a suspected or identified site of infection
- Subjects allergic to or hypersensitive to chlorhexidine gluconate. Before enrolling in the study, patients will be asked about previous exposure to chlorhexidine products and about their allergies. Those with potential allergic or adverse reaction to chlorhexidine will be excluded from the study.
Sites / Locations
- NYU Langone Health
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Chlorhexidine Gluconate Gel Dressing
Standard of Care
Arm Description
All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
Outcomes
Primary Outcome Measures
Change in Erythema Measurement
Drain site erythema will be measured with a ruler, in millimeters.
Number of participants in each category of skin induration (flat, soft, or firm)
2. Induration of skin will be measured by palpation of the skin around the drain by the clinician. This will be measured by assessing whether skin is flat, soft, or firm.
Change in distance between skin changes and normal looking skin
Extent of skin changes is measured using a ruler, in millimeters, to calculate the distance between skin changes and normal looking skin.
Total amount of drainage from drain site
Amount of drainage from drain site will be measured in cubic centimeters.
Number of participants who experience pain post-op
5. Pain will be measured by asking patients if they experience pain (yes or no) when the clinician presses on the drain site.
Number of participants in each category of quality of drainage (serous, sanguineous, or purulent)
Quality of drainage will be assessed by measuring thickness of drainage. Thickness of drainage will be measured as serous, sanguineous, or purulent.
Secondary Outcome Measures
Number of participants displaying signs of wound infection
Measures of wound infection will be assessed by documenting any signs of cellulitis or abscess around the drain.
Number of participants displaying sterility of seroma
Sterility of seroma will be measured by assessing whether the serous collection of fluid has absence of infection.
Antibiotic prescription rate
This will be measured as the number of days that patients are prescribed antibiotics.
Number of participants displaying presence of hematoma
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04656145
Brief Title
The Efficacy of Chlorhexidine Gluconate Gel Dressing in Preventing Surgical Drain Site Infection
Official Title
The Efficacy of Chlorhexidine Gluconate Gel Dressing in Preventing Surgical Drain Site Infection
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Study team was not able to enroll eligible patients.
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to evaluate if the application of chlorhexidine gluconate dressing on surgical drain sites can decrease drain site infection vs the standard of care (dry, sterile gauze).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Drain Site Complication
Keywords
Tegaderm
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A paired study design will be used and subjects will serve as their own control.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Chlorhexidine Gluconate Gel Dressing
Arm Type
Experimental
Arm Description
All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to receive the intervention.
Arm Title
Standard of Care
Arm Type
No Intervention
Arm Description
All subjects are receiving two surgical drains during a single operative procedure. This arm will be randomized to received standard drain care - gauze (no intervention).
Intervention Type
Device
Intervention Name(s)
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing
Intervention Description
On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
Primary Outcome Measure Information:
Title
Change in Erythema Measurement
Description
Drain site erythema will be measured with a ruler, in millimeters.
Time Frame
Day 0, up to Month 6
Title
Number of participants in each category of skin induration (flat, soft, or firm)
Description
2. Induration of skin will be measured by palpation of the skin around the drain by the clinician. This will be measured by assessing whether skin is flat, soft, or firm.
Time Frame
up to Month 6
Title
Change in distance between skin changes and normal looking skin
Description
Extent of skin changes is measured using a ruler, in millimeters, to calculate the distance between skin changes and normal looking skin.
Time Frame
Day 0, up to Month 6
Title
Total amount of drainage from drain site
Description
Amount of drainage from drain site will be measured in cubic centimeters.
Time Frame
Up to Month 6
Title
Number of participants who experience pain post-op
Description
5. Pain will be measured by asking patients if they experience pain (yes or no) when the clinician presses on the drain site.
Time Frame
Up to Month 6
Title
Number of participants in each category of quality of drainage (serous, sanguineous, or purulent)
Description
Quality of drainage will be assessed by measuring thickness of drainage. Thickness of drainage will be measured as serous, sanguineous, or purulent.
Time Frame
Day 0, up to Month 6
Secondary Outcome Measure Information:
Title
Number of participants displaying signs of wound infection
Description
Measures of wound infection will be assessed by documenting any signs of cellulitis or abscess around the drain.
Time Frame
up to Month 6
Title
Number of participants displaying sterility of seroma
Description
Sterility of seroma will be measured by assessing whether the serous collection of fluid has absence of infection.
Time Frame
up to Month 6
Title
Antibiotic prescription rate
Description
This will be measured as the number of days that patients are prescribed antibiotics.
Time Frame
up to Month 6
Title
Number of participants displaying presence of hematoma
Time Frame
up to Month 6
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 years or older
Receiving two surgical drains during one of the following types of operative procedures: breast reduction, breast augmentation, abdominoplasty, panniculectomy, brachioplasty, thigh lift, lower body lift, belt lipectomy, back latissimus dorsi reconstruction, bilateral breast reconstruction, or bilateral chest reconstruction. These drains may be in fairly close proximity to one another but they must emerge from different areas of the skin, that way they can be considered to be located in two different sites.
Exclusion Criteria:
Concurrent implantation of any foreign objects, such as a breast implant
Patients who receive postoperative antibiotics without a suspected or identified site of infection
Subjects allergic to or hypersensitive to chlorhexidine gluconate. Before enrolling in the study, patients will be asked about previous exposure to chlorhexidine products and about their allergies. Those with potential allergic or adverse reaction to chlorhexidine will be excluded from the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Chiu, MD
Organizational Affiliation
NYU Langone Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Thomas.Calahan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Learn more about this trial
The Efficacy of Chlorhexidine Gluconate Gel Dressing in Preventing Surgical Drain Site Infection
We'll reach out to this number within 24 hrs